Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Treatments

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Summary Background Recent clinical trials of anti-amyloid-beta (Aβ) monoclonal antibodies (mAbs) have demonstrated that the removal of Aβ in symptomatic patients can slow down the progression of Alzheimer’s disease (AD) and reinforce the “amyloid cascade” hypothesis. The analysis revealed that eight monoclonal antibodies (aducanumab, lecanemab, donanemab, bapineuzumab, gantenerumab, crenezumab, solanezumab, and ponezumab) demonstrated statistical improvements in cognitive outcomes. Specifically, the ADAS-cog [(total mAbs: SMD: -0.08, 95% CI: -0.11 to -0.04); (N-terminal-targeted mAbs: SMD: -0.08, 95% CI: -0.13 to -0.03)], CDR-SB [(total mAbs: SMD: -0.06, 95% CI: -0.12 to -0.00); (N-terminal-targeted mAbs: SMD: -0.08, 95% CI: -0.16 to -0.01)], and MMSE [(total mAbs: SMD: 0.06, 95% CI: 0.02 to 0.10); (N-terminal-targeted mAbs: SMD: 0.05, 95% CI: -0.00 to 0.10)] demonstrated significant improvement. In addition, the meta-analyses indicated that mAbs also had a statistically significant impact on reducing amyloid PET [(total mAbs: SMD: -1.13, 95% CI: -1.66 to -0.61); (N-terminal-targeted mAbs: SMD: -1.64, 95% CI: -2.27 to -1.02)], accelerating ventricle enlargement [(total mAbs: SMD: 0.22, 95% CI: 0.06 to 0.38); (N-terminal-targeted mAbs: SMD: 0.44, 95% CI: 0.30 to 0.57)], and causing whole-brain atrophy [(total mAbs: SMD: -0.14, 95% CI: -0.26 to -0.03); (N-terminal-targeted mAbs: SMD: -0.24, 95% CI: -0.41 to -0.07)], while increased the risk ARIA-E (total mAbs: RR: 9.79, 95% CI 7.83 to 12.26); (N-terminal-targeted mAbs: RR: 10.79, 95% CI: 8.61 to 13.52)] and ARIA-H [(total mAbs: RR: 1.28, 95% CI 0.98 to 1.67); (N-terminal-targeted mAbs: RR: 1.94, 95% CI: 1.64 to 2.29)]. However, no significant hippocampal volume atrophy was observed [(total mAbs: SMD: 0.00, 95% CI: -0.07 to 0.07); (N-terminal-targeted mAbs: SMD: -0.03, 95% CI: -0.13 to 0.07)]. It should be noted that all above effects were more significant in AD patients treated with N-terminal-targeted mAbs, as observed in subgroup analyses. Additionally, we observed a negative association between ventricular enlargement and Aβ clearance (Pearson’s r: -0.76), especially with the administration of N-terminal-targeted mAbs (Pearson’s r: -0.79), indicating a stronger effect on Aβ clearance. Interpretation The administration of mAbs that specifically target the N-terminus of Aβ showed promising results in reducing Aβ burden and ameliorating cognitive decline. In future anti-Aβ mAb development, our systematic rev

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Qiu, Y., Liu, M., Zhan, J., Liu, L., Zheng, J., Wu, D., et al. (2023). N-terminal-targeted anti-amyloid monoclonal antibodies illuminate the therapy for Alzheimer’s disease: a systematic review and comprehensive meta-analysis. medRxiv. https://doi.org/10.1101/2023.11.20.23298794

Vancouver

Qiu Y, Liu M, Zhan J, Liu L, Zheng J, Wu D, et al. N-terminal-targeted anti-amyloid monoclonal antibodies illuminate the therapy for Alzheimer’s disease: a systematic review and comprehensive meta-analysis. medRxiv. 2023. doi:10.1101/2023.11.20.23298794.

BibTeX

@article{qiu2023-1baddf3f,
  author  = {Qiu, Y. and Liu, M. and Zhan, J. and Liu, L. and Zheng, J. and Wu, D. and Wu, G. and Cai, Y. and others},
  title   = {{N-terminal-targeted anti-amyloid monoclonal antibodies illuminate the therapy for Alzheimer’s disease: a systematic review and comprehensive meta-analysis}},
  journal = {medRxiv},
  year    = {2023},
  doi     = {10.1101/2023.11.20.23298794},
  url     = {https://doi.org/10.1101/2023.11.20.23298794}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Study details

How this study scored 16/100
How this study's score is builtJournal tier 2 of 10; Journal's citation record 0 of 4; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 4 of 10; How recent 3 of 5; Sample size 1 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited left out, no data; Citations per year left out, no data; Impact for its field and year left out, no data; Cited by studies here left out, no data; Still being cited left out, no data; Senior author's track record left out, no data; Institution's track record left out, no data; Multicenter collaboration left out, no data; Indexed in PubMed 1 of 2; Free to read 0 of 2. 34 of the 62 points it could be judged on, which is 55 of 100. Raw total 55 of 100, shown as 16 because this is not a peer-reviewed research article.raw total 55 of 100capped at 16 — hatched points do not count

Preprint — not yet peer-reviewed. It scored 55 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 34 of the 62 points we could judge it on, which is 55 out of 100.

ComponentPointsWhy
Journal tier 2 / 10 Tier 4 — not a peer-reviewed journal (medRxiv)
Journal's citation record 0 / 4 Not a journal article, so the journal's record does not count
Study design 12 / 12 A systematic review of all the studies on the question
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 4 / 10 Preprint — not yet peer-reviewed. Hosted on a preprint server.
How recent 3 / 5 2023 — within 6 year(s) of the newest study here
Sample size 1 / 4 34 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited — / 7 No citation count (not found in OpenAlex) — left out of this score
Citations per year — / 5 No citation count or no year — left out of this score
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here — / 6 Not yet checked against this library's citation graph — left out of this score
Still being cited — / 4 No yearly citation counts — left out of this score
Senior author's track record — / 4 Senior author's record not available — left out of this score
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration — / 3 Institutions not listed — left out of this score
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 0 / 2 Behind a paywall — scores zero
Points 34 / 62 Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 34 of the 62 points we could judge it on is 55 out of 100.
Total 55 / 100 Capped to 16 because this is not a peer-reviewed article.

What each of these 20 components measures, and what this score is not →

Read the original

Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Treatments from nearby years

Also tagged “comprehensive-meta-analysis”

2 studies in the library carry the topic tag “comprehensive-meta-analysis”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →